未登録の方はこちらから登録できます。
TEL．03-5812-5270
FAX．03-3831-0495
E-mail：info@spi-information.com
市場調査のご依頼、専門分野のイベント・フォーラムの開催などは シード・プランニングにて承っております。
当サイトのコンテンツ利用時に送信される機密情報は、Verisign認証の元暗号化されて送信されます。
China Pharma Outsourcing Market By 2015
中国における2015年までの医薬アウトソーシング市場
中国は、世界中の製薬企業にとってのアウトソーシングの第一選択肢として、幅広く受け入れられています。過去8年間で、中国の医薬アウトソーシング業界は、年率平均48％で成長してきました。最初は化学業務だけでしたが、すべての業務要素を伴う完全な産業構造が、今形成され始めています。業界の成長は、多数の多国籍のサービス企業の参入に影響を受けています。さらに、ますます多くの伝統的な中国の製薬企業や、R&Dを重視した中国のバイテク企業もこのサービスに参入しています。現在、伝統的な中国の製薬企業150社と中国のバイテク企業20社が、中国の医薬アウトソーシング業界において、共同チームを形成しています。そして、この業界の収入は14億ドル以上を実現しています。
金融危機は、中国のこの業界に、短期的および長期的にどのような影響を及ぼすのでしょうか？この業界の5〜10年後はどうなっているでしょうか？この業界を依然として成長させる要因は何でしょうか？中国は、今後5〜10年後も費用効率が高いでしょうか？今後数年間で、人件費はどのくらい上がるでしょうか？これらは他の国々と比較してどうでしょうか？
本レポートは、以上のような質問に答えており、中国の医薬アウトソーシング業界や市場における最も包括的なレポートであります。中国のこの業界のサービス能力の発達傾向や市場規模を調査し、中国の医薬アウトソーシング業界の詳細を世界に初めて示しました。さらに、50以上のケーススタディの詳細な分析とともに、世界の製薬企業は中国でアウトソーシングをどのように実施するのか、どのようなアウトソーシングモデルが実行されているのかも明らかにしました。より重要なのは、本レポートが、中国のこの業界の将来成長を促進、あるいは抑制する要素について詳細に調査したことであります。
本レポートは、中国における医薬アウトソーシングに関心を持つ製薬、バイテク、財政投資、およびアウトソーシングサービスにおけるすべての専門家にとっての必読書であります。
目次
- Scope of the Report
- About Author
- Executive Summary
-
China's advantages in pharma outsourcing
Current market size, service capability and existing issues
From popular outsourcing models to future development trend: A series of case studies
Impact of financial crisis: Market development forecasts for 2009 and 2010
Future development: Years beyond 2010 - Chapter 1: China's Advantages in Pharma Outsourcing
-
Summary
1.1 Rich natural resources
1.1.1 Abundant, readily available natural resources1. Rich natural products
2. A large, drug-naïve patient pool
3. Abundant animal species1.2.2 Large, well-trained workforce1.2 Advantage of low cost labor
1.3 Attraction of potentially world largest pharmaceutical market
1.4 A complete industrial structure with all service elements starts emerging1.4.1 Rapid emerging of professional CROs and CMOs founded by Returnees1.5 Well developed business infrastructure
1.4.2 Increasing numbers of traditional Chinese pharma and R&D-oriented biotech companies join in outsourcing service
1.4.3 Influx of a large number of multinational service providers(MNCROs/MNCMOs)1.5.1 Well funded and equipped industrial/technology parks
1.5.2 R&D centers spreading all over the country
1.5.3 Well developed transportation system
1.5.4 Abundant supporting services1. Convenient logistics services
2. Financial service
3. Lounging - Chapter 2. Current Market Size, Service Capability and Existing Issues
-
Summary
2.1 Introduction
2.2 Current market size2.2.1 Entire industry market size
2.2.2 Current market size of each service sector1. Value chain of drug discovery, development and manufacturing process2.3 Current service capabilities
2. Market size of target identification and validation
3. Market size of lead discovery and optimization
4. Market size of preclinical research
5. Market size of clinical research
6. Current market size of contract manufacturing
7. Market distribution of each service sector2.3.1 Current service capability in early stage drug discovery1. Target identification and validation
2. Focused compound libraries
3. Lead discovery and optimization2.3.2 Current service capability in preclinical research1. In vitro/in vivo pharmacological property study
2. In vitro/in vivo ADME/Tox study
3. In vivo drug efficacy determination2.3.3 Current service capability in late stage development1. Service capability in clinical research
2. Logistics services for clinical trials2.3.4 Current service capability in contract manufacturing1. Service capability in process R&D and scale-up synthesis2.4 Industry boosted by the participation of Chinese pharma and biotech companies
2. Service capability in API production to support drug development and commercialization2.4.1 Outsourcing service provided by traditional Chinese pharmaceutical companies2.5 Existing Issues
2.4.2 Outsourcing service provided by fast growing, R&D-oriented Chinese biotech companies2.5.1 IP protection
2.5.2 Limited service capability
2.5.3 Limited skills in drug R&D
2.5.4 Majority players still small
2.5.5 Regulation in clinical trial and drug approval - Chapter 3. From Popular Outsourcing Models To Future Development Trend: A Series of Case Studies
-
Summary
3.1 Introduction
3.2 Outsourcing in China by major pharma companies: All types
3.3 Small biotech companies in China: Starting to embrace China opportunity
3.4 Outsourcing by generic drug makers: To secure supply stability by gaining ownership3.4.1 Pure contract manufacturing outsourcing3.5 Multinational CROs in China: To utilize rich, low cost resources
3.4.2 Taking partial ownership
3.4.3 Complete acquisition
3.4.4 Establishing wholly owned manufacturing facilities3.5.1 Clinical research service providers
3.5.2 Preclinical research service providers
3.5.3 Diagnostics and cardiac safety testing service providers - Chapter 4. Impact of Financial Crisis: Market Development Forecasts for 2009 and 2010
-
Summary
4.1 Introduction
4.2 Biotech companies hit hardest by the financial crisis
4.3 How terror attack at Mumbai of India will affect China pharma outsourcing industry
4.4 Qualitative analysis of the impact4.4.1 How major pharma and biotech companies will change their outsourcing behavior
4.4.2 How small biotech companies will change their outsourcing behavior1. Financially troubled small biotech companies can survive by outsourcing to China
2. How small biotech companies safely operate outsourcing in China: some practical advices4.4.3 How each service sector will be affected1. Impact on early stage drug discovery4.5 Quantitative analysis and forecast of market development for 2009 and 2010
2. Impact on preclinical development
3. Impact on clinical development
4. Impact on contract manufacturing4.5.1 Forecast of overall market development
4.5.2 Market development forecast of each service sector
4.5.3 How to compare with India pharma outsourcing market - Chapter 5. Future Development: Years beyond 2010
-
Summary
5.1 Introduction5.1.1 Global drug makers still need outsourcing services from China5.2 Drivers of the industry's future growth
5.1.2 Improved outsourcing environment and growing outsourcing demands by domestic companies will also drive the industry to further grow5.2.1 Advantage of still low cost labor1. Analysis of labor increase in next seven years(1) Salary increase caused by employee turnover will gradually fall flat2. Comparison of labor cost increase with other countries
(2) China is producing more college graduates than all industries of the country can absorb
(3) Living expense throughout entire country still varies dramatically
(4) More third tier cities in inner land are being rapidly developed5.2.2 Improved IP protection environment5.3 Will China follow the development model of the West or India?
5.2.3 Improved service capability and quality
5.2.4 Government support
5.2.5 Increasing outsourcing demands by small biotech companies pressured by financial crisis
5.2.6 More outsourcing demands by the emerging and growing domestic, R&D-oriented Chinese pharma/biotech companies5.3.1 Development pattern of Western pharma outsourcing industry5.4 Forecast of market development by 2015
5.3.2 Development pattern of Indian outsourcing industry
5.3.3 Which development model would China follow?5.4.1 Forecast of China pharma outsourcing market by 2015
5.4.2 Forecasts of market development of each service sector by 20151. Market development of outsourcing in early stage drug discovery
2. Market development of preclinical research outsourcing
3. Market development of outsourcing in clinical research
4. Market development of contract manufacturing(1) More APIs and finished drugs will be exported to the well regulated markets5.5 Three outsourcing waves successively drive the future growth
(2) More cGMP facilities compliance to the Western standards
(3) Service capability at traditional Chinese pharma companies will be greatly improved5.5.1 First wave: Outsourcing by major pharma companies
5.5.2 Second wave (soon to come): Outsourcing by small biotech companies
5.5.3 Third wave (to come in near future): Outsourcing by domestic drug companies1. More investment in R&D programs by Chinese pharma and biotech companies5.6 Forecast of Industry growth pattern
2. A growing number of venture capitalists investing in R&D-oriented Chinese pharma and biotech companies
3. Chinese government has pledged to increase R&D investment in its pharma industry5.6.1 More competition
5.6.2 More consolidation
5.6.3 More large players resulting from alliance with MNCROs
5.6.4 More Chinese companies will use service from MNCROs
5.6.5 More Chinese CROs and CMOs will have overseas operations
5.6.6 More MNCROs/MNCMOs will greatly expand their service facilities in China1. MNCROs/MNCMOs already in China would likely expand their facility and offer more services
2. More MNCROs will enter the Chinese market in near future5.6.7 More Chinese CROs/CMOs will have internal drug R&D programs5.7 Challenges to Chinese CROs and CMOs5.7.1 Rising labor cost
5.7.2 Abiding by the international rule of game
5.7.3 Competition from CROs/CMOs in other countries - List of Tables
-
Table 1. Comparison of China's technical workforce with other countries
Table 2. Comparison of labor cost in various locations of the world (FTE rate)
Table 3. China pharmaceutical market: Past development history and future development forecast
Table 4. Market growth history of China pharma outsourcing industry
Table 5. Current market size of target identification and validation
Table 6. Current market size of drug discovery service
Table 7. Current market size of preclinical research
Table 8. Current market size of clinical research
Table 9. Current market size of contract manufacturing service
Table 10. Market distribution of each service sector in entire China pharma outsourcing industry (2007 and 2008)
Table 11. CROs providing target identification and validation service
Table 12. CROs/CMOs providing focused compound libraries
Table 13. CROs providing lead discovery and optimization service
Table 14. CROs providing preclinical research service
Table 15. CROs providing clinical research service
Table 16. CROs providing regulatory service
Table 17. CROs/CMOs providing contract manufacturing service (including chemical process R&D)
Table 18. CROs/CMOs possessing FDA or EMEA certified cGMP production facility
Table 19. Chinese pharma companies involved in contract manufacturing service -76
Table 20. Major Chinese biotech companies and their capabilities
Table 21. Classification and definition of contract pharmaceutical research service levels and analysis of where the current service capabilities of China-based CROs/CMOs stand
Table 22. Comparison of a typical CRO in China, India and a Western country
Table 23. Market development forecast of China pharma outsourcing industry(2009 and 2010)
Table 24. Market development forecast of each service sector in 2009 and 2010
Table 25. Growth prediction of China's CRO and CMO market in 2009 and 2010
Table 26. Comparison of market value between China and India in 2009 and 2010
Table 27. Forecast of labor cost climbing in China pharma outsourcing industry(FTE rate)
Table 28. Comparison of labor cost increase in countries around the world in next seven years (FTE rate)
Table 29. Comparison of cost saving (%) between China and other countries in 2010 and 2015
Table 30. Development history of WuXi PharmaTech and forecast of its future development
Table 31. Market growth forecast of China pharma outsourcing industry after 2010
Table 32. Market growth forecast of early stage drug discovery service after 2010
Table 33. Market growth forecast of preclinical research service after 2010
Table 34. Market growth forecast of clinical development service after 2010
Table 35. Market growth forecast of contract manufacturing service after 2010
Table 36. Foreign VCs having invested in Chinese pharma/biotech companies
Table 37. China-based CROs/CMOs with headquarters/offices in the West
Table 38. China-based CROs/CMOs founded by Western entrepreneurs - List of Figures
-
Figure 1. Development of Chinese pharmaceutical market: Past and future
Figure 2. Development of each drug market section
Figure 3. Chinese pharmaceutical market composition of 2008
Figure 4. Distributions of Chinese CROs/CMOs in each technical area
Figure 5. Profile of Suzhou Biobay
Figure 6. An overview of current situation of China pharma outsourcing industry
Figure 7. Market development of China pharma outsourcing industry
Figure 8. Value chain of drug discovery, development and manufacturing
Figure 9. 2008 Market share of each service sector
Figure 10. An overall picture of outsourcing activities in China
Figure 11. Summary of latest restructuring activities taken by biotech industry
Figure 12. Biotech industry under financial crisis
Figure 13. How outsourcing to China will be affected by financial crisis
Figure 14. Market value of each service sector in 2009 and 2010
Figure 15. China's CRO and CMO market value in 2009 and 2010
Figure 16. Comparison of pharma outsourcing market size between China and India
Figure 17. Climbing of labor cost in China pharma outsourcing industry(between 2008 and 2015)
Figure 18. Comparison of labor cost increase in China with other countries(from 2008 to 2015)
Figure 19. Cost saving comparison (%) between China and other countries(in 2010 and 2015)
Figure 20. WuXi PharmaTech's staff growth history and forecast
Figure 21. WuXi PharmaTech's revenue growth history and forecast
Figure 22. Market development forecast of China pharma outsourcing industry after 2010
Figure 23. Market development forecast of early stage drug discovery service after 2010
Figure 24. Market development forecast of preclinical development service after 2010
Figure 25. Market development forecast of clinical development service after 2010
Figure 26. Market growth of China's contract manufacturing service after 2010 - List of Case Studies
-
Case study 1. Company profile of India's Dr. Reddy's Laboratories
Case study 2. Company profile of China's Harbin Pharmaceutical Group
Case study 3. Pfizer in China - Initially falling behind others but becoming more aggressive now
Case study 4. Sanofi Aventis (SA) in China - Focusing on research
Case study 5. GlaxoSmithKline (GSK) in China - Determined to turn "Made in China" to "Discovered in China"
Case study 6. Johnson & Johnson (J&J) in China - Focusing on outsourcing
Case study 7. Roche in China - Considering China as an important market for its future development
Case study 8. Novartis in China - Having a long term plan to tap Chinese drug market
Case study 9. AstraZeneca (AZ) in China: Most active among all major pharma companies in China
Case study 10. Eli Lilly in China - Taking different approaches than all other peer competitors
Case study 11. Wyeth in China - Focusing on China's nutri-ceutics market
Case study 12. Bayer in China - Focusing on manufacturing and marketing drug products in China
Case study 13. LEAD Therapeutics with ShangPharma - A risk-sharing model with Chinese CRO investing in client company
Case study 14. Curis with ChemPartner - To stretch the dollar value of cash reserve by allocating part of drug R&D program to China----123
Case study 15. ChinaBio Therapeutics - To leverage the full potential of China's cost-effectiveness by operating entire drug R&D program in China
Case study 16. Ascenta Therapeutics in China - Strategically positioning
Case study 17. GNI with Shanghai Genomics - From partnership to acquisition
Case study 18. Bicoll in China - From a technology developer to becoming a contract research service provider
Case study 19. Boehringer Ingelheim in China
Case study 20. Krka Pharmaceuticals and Menovo Pharmaceuticals - Krka owning 7.5% stake in Menovo
Case study 21. Oxea with Chengxing Group - Forming a JV
Case study 22. Hovione acquired 75% stake of Hisyn Pharmaceutical Co.
Case study 23. Actavis acquired 90% stake of Zhejiang Chiral Medicine Chemicals
Case study 24. Degussa in China
Case study 25. Lonza in China
Case study 26. Covance in China - Recently established a central lab in Shanghai
Case study 27. PPD in China
Case study 28. Quintiles Transnational in China
Case study 29. MDS Pharma Services in China - Recently established a central Lab in Beijing
Case study 30. Charles River Laboratories in China: Acquired BioExplorer
Case study 31. MPI Research in China - Forming a JV with Medicilon
Case study 32. Bridge Pharmaceuticals in China - Established wholly owned animal testing facility in Beijing
Case study 33. Biomagnetics Diagnostics in China
Case study 34. Cordium Links in China - Forming a JV for cardiac safety testing
Case study 35. AstraZeneca contracting out IP sensitive drug research to Chinese CRO
Case study 36. Promega Corporation outsourced IP sensitive research to China
Case study 37. Novartis is conducting first-class drug research in China
Case study 38. Chinese pharma companies following the international rules
Case study 39. Merger between two Chinese CROs
Case study 40. Development history of a typical Chinese CRO to demonstrate the development pattern of China pharma outsourcing industry
Case study 41. A foreign CRO's development history to illustrate the possible future development pattern of China's outsourcing industry
Case study 42. Compound libraries enriched with protein kinase inhibitors
Case study 43. Fast growing Zhejiang Hisun Pharmaceutical Co. Ltd.
Case study 44. Fast rising Zhejiang Huahai Pharmaceutical Co. Ltd.
Case study 45. More China-based CROs/CMOs are preparing for cGMP certification by the FDA and/or the EMEA
Case study 46. Alliance between two China-based CROs
Case study 47. Alliance between a Chinese CRO and two foreign CROs
Case study 48. Alliance of 33 China-based CROs
Case study 49. Fast growing Shanghai Medicilon by partnering with MPI Research
Case study 50. Chinese CRO utilizing multinational CRO's technologies
Case study 51. Global Research Services expanding in China
Case study 52. Latest entrance by Drug Information Association (DIA) - Company Index
-
Professional Chinese CROs and CMOs
Traditional Chinese pharmaceutical companies involved in outsourcing service
Chinese biotech companies involved in outsourcing service
Multinational service providers having service facilities in China
Chinese research institutions collaborating with Western pharma companies
Foreign drug companies outsourcing in China - Appendix
-
Appendix I. Research methodology
Appendix II. About JZMed, Inc.
発刊日
2009/01/01
体裁
PDF / 225ページ
販売価格
1,745USD
発行
JZMed Inc
備考
※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。
関連カテゴリ
購入・お問い合わせ
